Table 2.
Association of survivin and VEGF-C protein expression with clinicopathological features in breast cancer patients
| Variable | n | Survivin- | Survivin+ | χ2 | p | VEGF-C - | VEGF-C + | χ2 | p |
|---|---|---|---|---|---|---|---|---|---|
|
Age |
|
|
|
0 |
1 |
|
|
0.965 |
0.326 |
|
≤45 years |
36 |
6 |
30 |
|
|
6 |
30 |
|
|
|
>45 years |
72 |
12 |
60 |
|
|
18 |
54 |
|
|
|
Tumor size |
|
|
|
9.305 |
0.01 |
|
|
4.102 |
0.129 |
|
T1 |
39 |
12 |
27 |
|
|
12 |
27 |
|
|
|
T2 |
60 |
6 |
54 |
|
|
9 |
51 |
|
|
|
T3 |
9 |
0 |
9 |
|
|
3 |
6 |
|
|
|
Histological grade |
|
|
|
0.873 |
0.350 |
|
|
0.175 |
0.675 |
|
I + II |
99 |
15 |
84 |
|
|
21 |
78 |
|
|
|
III |
9 |
3 |
6 |
|
|
3 |
6 |
|
|
|
Pathological style |
|
|
|
0.169 |
0.681 |
|
|
0 |
1 |
|
ISC |
12 |
3 |
9 |
|
|
3 |
9 |
|
|
|
IC |
96 |
15 |
81 |
|
|
21 |
75 |
|
|
|
Lymph node metastasis |
|
|
|
16.283 |
0.000 |
|
|
18.544 |
0.000 |
|
Negative |
30 |
12 |
18 |
|
|
15 |
15 |
|
|
|
Positive |
78 |
6 |
72 |
|
|
9 |
69 |
|
|
|
C-erBb-2 |
|
|
|
8.269 |
0.004 |
|
|
4.354 |
0.037 |
|
positive(3 + ) |
12 |
6 |
6 |
|
|
6 |
6 |
|
|
|
negative(0-2 + ) |
96 |
12 |
84 |
|
|
18 |
78 |
|
|
|
ER |
|
|
|
0.617 |
0.432 |
|
|
0.882 |
0.348 |
|
positive |
63 |
9 |
54 |
|
|
12 |
51 |
|
|
|
negative |
45 |
9 |
36 |
|
|
12 |
33 |
|
|
|
PR |
|
|
|
0 |
1 |
|
|
1.929 |
0.165 |
|
positive |
54 |
9 |
45 |
|
|
15 |
39 |
|
|
|
negative |
54 |
9 |
45 |
|
|
9 |
45 |
|
|
|
TNM stage |
|
|
|
10.800 |
0.001 |
|
|
6.027 |
0.014 |
|
I, II |
72 |
18 |
54 |
|
|
21 |
51 |
|
|
| III, IV | 36 | 0 | 36 | 3 | 33 |
ISC, in situ carcinoma; IC, invasive carcinoma.